Below is Validea's guru fundamental report for STRYKER CORP (SYK). Of the 22 guru strategies we follow, SYK rates highest using our Multi-Factor Investor model based on the published strategy of ...

GSK agrees €1.4bn deal to take full control of CureVac's mRNA vaccines for flu and COVID-19, as CureVac slashes staff and pivots to oncology. Skip to main content Monday 23 June 2025 ...

Moderna’s arch-rival in the mRNA vaccine category, BioNTech, is also developing a personalised cancer vaccine called BNT111, based on four melanoma-associated antigens, in combination with ...

YieldMax MRNA Option Income Strategy ETF (MRNY) Dividend History. Data is currently not available No data available. Data ...